Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
9.25
+2.25 (32.14%)
Jul 17, 2025, 4:00 PM - Market closed
Scilex Holding Company Employees
Scilex Holding Company had 115 employees as of December 31, 2024. The number of employees increased by 10 or 9.52% compared to the previous year.
Employees
115
Change (1Y)
10
Growth (1Y)
9.52%
Revenue / Employee
$440,957
Profits / Employee
-$647,913
Market Cap
50.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 10 | 9.52% |
| Dec 31, 2023 | 105 | 15 | 16.67% |
| Dec 31, 2022 | 90 | 14 | 18.42% |
| Dec 31, 2021 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SCLX News
- 24 days ago - Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - GlobeNewsWire
- 2 months ago - Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL - GlobeNewsWire
- 2 months ago - Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. - GlobeNewsWire
- 2 months ago - Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada - GlobeNewsWire